• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在西班牙,使用质量调整生命年来对卫生技术进行经济评估:对 1990-2009 年文献的综述。

The use of quality-adjusted life-years in the economic evaluation of health technologies in Spain: a review of the 1990-2009 literature.

机构信息

Johnson & Johnson, Madrid, Spain.

出版信息

Value Health. 2011 Jun;14(4):458-64. doi: 10.1016/j.jval.2010.10.039.

DOI:10.1016/j.jval.2010.10.039
PMID:21669370
Abstract

OBJECTIVE

To appraise economic evaluations of health technologies that included quality-adjusted life-years (QALYs) as an outcome measure conducted over the past 20 years in Spain.

METHODS

A systematic review of the literature was conducted. Economic evaluations that included QALYs as an outcome measure, conducted in Spain and published between January 1990 and December 2009 were identified. Primary and gray literature sources were reviewed.

RESULTS

A total of 60 articles and 4 health technology assessment reports were included. Key findings were 1) the vast majority of articles (77.1%) referred to therapeutic interventions; 2) 63.2% dealt with pharmaceutical products and much fewer with preventive strategies, medical devices, or diagnostic interventions; 3) most evaluations referred to cardiovascular- (19.8%), respiratory- (16.3%), and cancer- (13.0%) related processes; 4) 80.3% were based on a theoretical model, most commonly Markov models (71.4%); 5) 67.3% adopted the National Health System perspective; 6) information on the methods used to describe the health states was given in 45.1% of studies; 7) 40.3% used the EuroQoL-5D to elicit preferences, whereas 66.1% gave no details on the methods applied to determine patients' choices; 8) it was possible to state who completed the questionnaires in only 17.7% of studies; 9) 77.1% of the interventions assessed were below the €30,000/QALY suggested affordable threshold in Spain.

CONCLUSIONS

An increasing number of economic evaluations using QALYs had been conducted. Most of them relied on theoretical models. Several methodological issues remain unsolved. Great disparity exists regarding the reporting of the methods used to determine health states and utility values.

摘要

目的

评价过去 20 年在西班牙进行的纳入质量调整生命年(QALY)作为结果指标的卫生技术经济评估。

方法

对文献进行系统回顾。纳入 1990 年 1 月至 2009 年 12 月期间在西班牙进行的纳入 QALY 作为结果指标的经济评估,并查阅初级和灰色文献来源。

结果

共纳入 60 篇文章和 4 篇卫生技术评估报告。主要发现包括:1)绝大多数文章(77.1%)涉及治疗干预措施;2)63.2%涉及药品,而涉及预防策略、医疗器械或诊断干预措施的文章较少;3)大多数评估涉及心血管疾病(19.8%)、呼吸系统疾病(16.3%)和癌症(13.0%);4)80.3%基于理论模型,最常见的是 Markov 模型(71.4%);5)67.3%采用国家卫生系统视角;6)45.1%的研究提供了描述健康状况所用方法的信息;7)40.3%使用 EuroQoL-5D 来获取偏好,而 66.1%未详细说明用于确定患者选择的方法;8)仅在 17.7%的研究中可以说明谁完成了问卷调查;9)评估的干预措施中,77.1%的干预措施低于西班牙建议的 30,000 欧元/QALY 可负担阈值。

结论

越来越多的经济评估使用 QALY 进行。它们中的大多数依赖于理论模型。一些方法学问题仍未解决。在确定健康状态和效用值的方法报告方面存在很大差异。

相似文献

1
The use of quality-adjusted life-years in the economic evaluation of health technologies in Spain: a review of the 1990-2009 literature.在西班牙,使用质量调整生命年来对卫生技术进行经济评估:对 1990-2009 年文献的综述。
Value Health. 2011 Jun;14(4):458-64. doi: 10.1016/j.jval.2010.10.039.
2
A systematic review and economic evaluation of epoetin alpha, epoetin beta and darbepoetin alpha in anaemia associated with cancer, especially that attributable to cancer treatment.促红细胞生成素α、促红细胞生成素β和达比加群酯治疗癌症相关性贫血(尤其是癌症治疗所致贫血)的系统评价与经济学评估
Health Technol Assess. 2007 Apr;11(13):1-202, iii-iv. doi: 10.3310/hta11130.
3
Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy.利用预后信息为乳腺癌患者选择辅助性全身治疗的成本效益
Health Technol Assess. 2006 Sep;10(34):iii-iv, ix-xi, 1-204. doi: 10.3310/hta10340.
4
A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.拓扑替康治疗卵巢癌的临床有效性和成本效益的快速系统评价。
Health Technol Assess. 2001;5(28):1-110. doi: 10.3310/hta5280.
5
Home treatment for mental health problems: a systematic review.心理健康问题的居家治疗:一项系统综述
Health Technol Assess. 2001;5(15):1-139. doi: 10.3310/hta5150.
6
The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.卡莫司汀植入剂与替莫唑胺治疗新诊断的高级别胶质瘤的有效性和成本效益:一项系统评价与经济学评估
Health Technol Assess. 2007 Nov;11(45):iii-iv, ix-221. doi: 10.3310/hta11450.
7
Diagnostic management strategies for adults and children with minor head injury: a systematic review and an economic evaluation.成人和儿童轻微头部损伤的诊断管理策略:系统评价和经济评估。
Health Technol Assess. 2011 Aug;15(27):1-202. doi: 10.3310/hta15270.
8
The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.心脏再同步治疗(双心室起搏)用于心力衰竭的临床疗效及成本效益:系统评价与经济学模型
Health Technol Assess. 2007 Nov;11(47):iii-iv, ix-248. doi: 10.3310/hta11470.
9
Elucigene FH20 and LIPOchip for the diagnosis of familial hypercholesterolaemia: a systematic review and economic evaluation.Elucigene FH20 和 LIPOchip 用于家族性高胆固醇血症的诊断:系统评价和经济评估。
Health Technol Assess. 2012;16(17):1-266. doi: 10.3310/hta16170.
10
The clinical effectiveness and cost-effectiveness of enzyme replacement therapy for Gaucher's disease: a systematic review.戈谢病酶替代疗法的临床疗效和成本效益:一项系统评价。
Health Technol Assess. 2006 Jul;10(24):iii-iv, ix-136. doi: 10.3310/hta10240.

引用本文的文献

1
Cost-effectiveness of brief structured interventions to discontinue long-term benzodiazepine use: an economic analysis alongside a randomised controlled trial.简短结构化干预措施用于停用长期苯二氮䓬类药物使用的成本效益:一项与随机对照试验同步进行的经济分析。
HRB Open Res. 2020 Jun 3;3:33. doi: 10.12688/hrbopenres.13049.1. eCollection 2020.
2
Understanding the global measurement of willingness to pay in health.了解全球范围内健康领域支付意愿的衡量情况。
J Mark Access Health Policy. 2020 Feb 15;8(1):1717030. doi: 10.1080/20016689.2020.1717030. eCollection 2020.
3
Economic and epidemiologic impact of guidelines for early ART initiation irrespective of CD4 count in Spain.
西班牙无论 CD4 计数如何,均遵循早期 ART 启动指南的经济和流行病学影响。
PLoS One. 2018 Nov 5;13(11):e0206755. doi: 10.1371/journal.pone.0206755. eCollection 2018.
4
Health Economic Evaluations of Cancer in Brazil: A Systematic Review.巴西癌症的卫生经济评估:一项系统综述。
Front Public Health. 2018 Jul 27;6:205. doi: 10.3389/fpubh.2018.00205. eCollection 2018.
5
Liraglutide Versus Lixisenatide: Long-Term Cost-Effectiveness of GLP-1 Receptor Agonist Therapy for the Treatment of Type 2 Diabetes in Spain.利拉鲁肽与利司那肽对比:西班牙2型糖尿病治疗中GLP-1受体激动剂疗法的长期成本效益
Diabetes Ther. 2017 Apr;8(2):401-415. doi: 10.1007/s13300-017-0239-6. Epub 2017 Feb 21.
6
The quality of reporting methods and results of cost-effectiveness analyses in Spain: a methodological systematic review.西班牙成本效益分析报告方法与结果的质量:一项方法学系统评价
Syst Rev. 2016 Jan 7;5:6. doi: 10.1186/s13643-015-0181-5.
7
The use of cost per life year gained as a measurement of cost-effectiveness in Spain: a systematic review of recent publications.使用获得的每生命年成本作为西班牙成本效益的衡量标准:对近期出版物的系统回顾。
Eur J Health Econ. 2012 Dec;13(6):723-40. doi: 10.1007/s10198-011-0326-y. Epub 2011 Jun 10.